Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280137 | 0.87 | SLC6A3 (0.56) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL4326100 | 0.87 | SLC6A3 (0.56) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL27958806 | 0.87 | IRAK4 (0.68) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL2942817 | 0.85 | IRAK4 (0.66) | IRAK4ALDH1A1ACHEHSD17B10IDO1 | |
| SCHEMBL22995188 | 0.85 | SLC6A3 (0.57) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL15528489 | 0.85 | TSHR (0.74) | IRAK4TSHRALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL3791612 | 0.84 | SLC6A3 (0.53) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL7795902 | 0.84 | IRAK4 (0.51) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL15814877 | 0.84 | IRAK4 (0.51) | IRAK4SLC6A3TSHRLMNAALDH1A1 | |
| SCHEMBL6014143 | 0.84 | IRAK4 (0.64) | IRAK4ALDH1A1ACHEHSD17B10IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812114-B | Isoxazole derivative, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| CN-110300579-A | Sulfamoyl aryl derivatives and its purposes for being used to treat liver fibrosis as drug | 詹森药业有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-105273003-B | Isocarbophos haptens and its preparation method and application | 深圳市检验检疫科学研究院 | 2017-12-01 | — | — | CN | disclosed |
| CN-105612158-A | Antagonists of somatostatin receptor subtype 5 (sstr5) | TAKEDA PHARMACEUTICALS CO | 2016-05-25 | — | — | CN | disclosed |
| CN-104829756-A | Solid catalyst component for olefin polymerization, and preparation method and application thereof | CHINESE ACAD INST CHEMISTRY | 2015-08-12 | — | — | CN | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| CN-1460097-A | NF-kB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY SEIYAKU CO LTD (JP) | 2003-12-03 | — | — | CN | disclosed |
| US-4148900-A | ANTIALLERGIC | CARLO ERBA S.P.A. (IT) | 1979-04-10 | — | — | US | disclosed |
| US-4115567-A | TREATMENT OF ALLERGIES | CARLO ERBA S. P. A. (IT) | 1978-09-19 | — | — | US | disclosed |
| US-4083953-A | ANTIALLERGENS | CARLO ERBA, S.P.A. (IT) | 1978-04-11 | — | — | US | disclosed |
| US-4065467-A | ANTIALLERGENS, ANTIULCER AGENTS, TREATMENT OF RESPIRATORY SYSTEM AND PULMONARY DISORDERS | CARLO ERBA, S. P. A. (IT) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | HTR2B, HTR3B, HTR1A | IRAK4 2895/4885SLC6A3 328/4885TSHR 1013/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | IRAK4 2691/4885SLC6A3 4723/4885TSHR 3370/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | IRAK4 2691/4885SLC6A3 4723/4885TSHR 3370/4885 |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | HTR2B, HTR3B, HTR1A | IRAK4 2895/4885SLC6A3 328/4885TSHR 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.